Download 6659

ACRIN 6659
MR Imaging and MR Spectroscopic Imaging of Prostate Cancer
Prior to Radical Prostatectomy: a Prospective Multi-Institutional
Clinicopathological Study
Principal Investigator: Jeffrey C. Weinreb, M.D.
Protocol Statistician: Jeffrey D. Blume, Ph.D.
Lead Biostatistician: Jean Cormack, Ph.D.
Lead Data Manager: Karan Boparai, RT (R) (M)
Project Manager: Donna Hartfeil, RN, BSN
Abstract:
Endorectal MRI is emerging as the most accurate modality for the local imaging of prostate
cancer. MR spectroscopic imaging (MRSI) of the prostate depicts the altered metabolism
associated with prostate cancer, and is performed in conjunction with standard endorectal MRI.
Combined endorectal MRI and MRSI provides an integrated anatomic and metabolic depiction
of prostate cancer, and appears superior to endorectal MRI alone. The primary aim of this
protocol is to evaluate the accuracy of combined MRI/MRSI performed at multiple institutions in
the localization of prostate cancer and its incremental benefit on diagnostic accuracy when
compared to MRI alone. One hundred and thirty-four patients with documented prostate cancer
who are planned for radical prostatectomy will undergo preoperative combined MRI/MRSI at 1
of 5 institutions. Five independent readers will interpret all scans. Reference information will be
derived from central pathological examination of surgical specimens. Secondary objectives
include determination of the incremental effect of combined MRI/MRSI on inter-observer
agreement when compared to MRI alone and determination of the accuracy of combined
MRI/MRSI when compared to other available information on tumor extent derived from digital
rectal examination, prostate specific antigen (PSA) level, Gleason score, and Partin nomogram.
For full protocol text and data forms, click here